Mecamylamine: Targacept

IDrugs

Volumn 9, Issue 3, 2006, Pages 205-217

  Singh, Abhay ^a,b   Das, Deepak K ^c   Kelley, Michael E ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b St Mary's Regional Med Center   (United States)

^c Androscoggin Valley Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; DEXTROMETHORPHAN; HEXAMETHONIUM; INVERSENE; MECAMYLAMINE; NEUROLEPTIC AGENT; NICOTINE PATCH; PENTOLONIUM TARTRATE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TC 5214; TC 5231; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANOREXIA; ANTIHYPERTENSIVE ACTIVITY; ANXIETY; ANXIETY DISORDER; ARTICLE; ASTHENIA; ATTENTION DEFICIT DISORDER; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE DEFECT; CONSTIPATION; CONVULSION; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; GLOSSITIS; HUMAN; HYPERTENSION; ILEUS; LOW DRUG DOSE; MAJOR DEPRESSION; MEMORY DISORDER; MENTAL DISEASE; MORPHINE ADDICTION; MUSCLE WEAKNESS; MYDRIASIS; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; HUMANS; MECAMYLAMINE; NICOTINIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION; SUBSTANCE-RELATED DISORDERS; TOURETTE SYNDROME;

EID: 33644944478     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. 78 Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence. Rose JE, Levin ED PHARMACOL BIOCHEM BEHAV 1992 41 1219-226
2. 09 The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, Norman AB BIOL PSYCHIATRY 1992 318 832-840
3. 01 Layton - nicotinic acetylcholine receptor antagonists. Layton Bioscience Inc COMPANY WORLD WIDE WEB SITE 1999 October 19
4. 43 Mecamylamine in Tourette's syndrome: A two-year retrospective case study. Silver AA, Shhytle RD, Sanberg PR J CHILD ADOLESC PSYCHOPHARMACOL 2000 10 2 59-68
5. 86 Analysis of mecamylamine steroisomers on human nicotinic receptor subtypes. Papke RL, Sanberg PR, Shytle RD NEUROPHARM CONF 2000 10 Nov 2-4 P1.22
6. 88 Mecamylamine (mec) differentiates two district mechanisms underlying nicotine (nic) sensitization to once-weekly nic injection. Wilkins LH, Crooks PA, Bardo MT, Dwoskin LP NEUROPHARM CONF 2000 10 Nov 2-4 P5.6
7. 95 Pharmacokinetic evaluation of mecamylamine (Inversine) in adults. Jacobs A, Bowesox S, Kisick JC, Sanberg PR, Shytle RD NEUROPHARM CONF 2000 10 Nov 2-4 P5.15
8. 98 Mecamylamine prolongs the duration of haloperidol-induced catalepsy in rats. Newman MB, Alvarez F, Potts SE, Manresa JJ, Shytle RD, Sanberg PR NEUROPHARM CONF 2000 10 Nov 2-4 P5.16
9. 03 Safety and exploratory study of mecamylamine monotherapy for Tourette's syndrome. Silver AA, Shytle RD, Sheehan DV, Sheehan KH, Ramos A, Sanberg PR NEUROPHARM CONF 2000 10 Nov 2-4 P6.10
10. 85 Targacept acquires Inversine in bid to expand CNS portfolio. Targacept Inc PRESS RELEASE 2002 August 27
11. 21 Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder. Silver AA, Shytle RD, Sheehan RD, Sheehan DV, Ramos A, Sanberg PR J AM ACAD CHILD ADOLESC PSYCHIATRY 2001 40 9 1103-1110
12. 22 Mecamylamine effects on haloperidol-induced catalepsy and defecation. Sanberg PR, Nevman MB, Manresa JJ, Potts SE, Alvarez F, Cahill DW, Shytle RD INT J NEUROSCI 2001 109 1-2 81-90
13. 26 Mecamylamine: New therapeutic uses and toxicity/risk profile. Young JM, Shytle RD, Sanberg PR, George TP CLIN THER 2001 23 4 532-565
14. 39 Depression & Anxiety - SMi Conference, Shining Light Into Dark Corners, London, UK. Durrance A IDDB MEETING REPORT 2003 May 12-13
15. 74 Neuronal nicotinic acetylcholine receptor (nAChR) modulation in anxiety and depression. Dunbar G SMI CONF - DEPRESSION ANXIETY 2003 May 12-13
16. 97 BID 2003 - International Biotechnology Convention and Exhibition (Part IV) - Overnight Report. Waterworth C IDDB MEETING REPORT 2003 June 21-25
17. 66 Form S-1 - Targacept Inc. Targacept Inc FORM S-1 2004 May 14
18. 96 Neuronal nicotinic receptor inhibition for treating mood disorders preliminary controlled evidence with mecamylamine. Shytle RD, Silver AA, Sheehan KH, Sheehan DV, Sanberg PR DEPRESSION ANXIETY 2002 16 3 89-92
19. 47 Nicotinic acetylcholine receptor system and neuropsychiatric disorders. Singh A, Potter A, Newhouse P IDRUGS (2004) 7 12 1096-1103
20. 13 Mecamylamine (Inversine): An old antihypertensive with new research directions. Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR J HUM HYPERTENS 2002 16 7 453-457
21. 65 Pharmacology of mecamylamine. Ford RV, Madison JC, Moyer JH AM J MED SCI 1956 232 2 129-143
22. 73 Overview of nicotinic receptors and their roles in the central nervous system. Dani JA BIOL PSYCHIATRY (2001) 49 3 166-174
23. 79 The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist. Varanda WA, Aracava Y, Sherby SM, VanMeter WG, Eldefrawi ME, Albuquerque EX MOL PHARMACOL 1985 28 2 128-137
24. 85 Antagonist activities of mecamylamine and nicotine show reciprocal dependence on □ subunit sequence in the second transmembrane domain. Webster JC, Francis MM, Porter JK, Robinson G, Stokes C, Horenstein B, Papke RL BR J PHARMACOL 1999 127 6 1337-1348
25. 93 Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Nisell M, Nomikos GG, Svensson TH SYNAPSE 1994 16 136-44
26. 96 Lack of cholinergic regulation of vasopressin and norepinephrine responses to hypertonic saline in humans. Pascualy M, Peskind ER, Wingerson D, van Belle G, Veith RC, Dorsa DM, Raskind MA PSYCHONEUROENDOCRINOLOGY 1995 20 7 679-691
27. 05 Serotonergic and cholinergic interaction in the regulation of pituitary-adrenal function in rats. Kile JP, Turner BB EXPERIENTIA 1985 41 9 1123-1127
28. 07 Some consequences of long-term mecamylamine administration to experimental animals. Vidrio H, Gomez J, Rodriguez R, Pardo EG J PHARMACOL EXP THER 1965 149 98-105
29. 12 The pharmacological actions of pempidine and its ethyl homologue. Spinks A, Young EH, Farrington JA, Dunlop D BR J PHARMACOL CHEMOTHER 1958 13 4 501-520
30. 13 Mecamylamine in control of hyperreflexia. Braddom RL, Johnson EW ARCH PHYS MED REHABIL 1969 50 8 448-453
31. 16 Autonomic dysreflexia. A survey of current treatment. Braddom RL, Rocco JF AM J PHYS MED REHABIL 1991 70 5 234-241
32. 18 Neuromuscular disorders in mecamylamine therapy. Doyal AE, Neilson GH BR MED J 1956 2 1431-1432
33. 25 Effects of mecamylamine on spontaneous EEG and performance in smokers and non-smokers. Pickworth WB, Fant RV, Butschky MF, Henningfield JE PHARMACOL BIOCHEM BEHAV 1997 56 2 181-187
34. 32 Mecamylamine does not precipitate withdrawal in cigarette smokers. Eissenberg T, Griffiths RR, Stitzer ML PSYCHOPHARMACOLOGY 1996 127 4 328-336
35. 33 Acute nicotinic blockade produces cognitive impairment in normal humans. Newhouse PA, Potter A, Corwin J, Lenox R PSYCHOPHARMACOLOGY 1992 108 4 480-484
36. 36 Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Newhouse PA, Potter A, Corwin J, Lenox R NEUROPSYCHOPHARMACOLOGY 1994 10 2 93-107
37. 41 Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV CLIN PHARMACOL THER 1994 56 186-99
38. 44 Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. Rose JE, Behm FM, Westman EC EXP CLIN PSYCHOPHARMACOL 1998 6 3 331-343
39. 57 Nicotine for the treatment of Tourette's syndrome. Sanberg PR, Silver AA, Shytle RD, Philipp MK, Cahill DW, Fogelson HM, McConville BJ PHARMACOL THER 1997 74 1 21-25
40. 58 Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: An open study. Dursun SM, Reveley MA PSYCHOL MED 1997 27 2 483-487
41. 59 Transdermal nicotine and haloperidol in Tourette's disorder: A double-blind placebo-controlled study. Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR J CLIN PSYCHIATRY 2001 62 9 707-714
42. 62 Transdermal nicotine for Tourette's syndrome. Sanberg PR, Silver AA, Shytle RD, Philipp MK, Cahill DW, Fogelson HM, McConville BJ DRUG DEV RES (1996) 38 290-298.
43. 67 Sustained nicotine exposure differentially affects α 3 β 2 and α 4 β 2 neuronal nicotinic receptors expressed in Xenopus oocytes. Hsu YN, Amin J, Weiss DS, Wecker L J NEUROCHEM 1996 66 2 667-675
44. 74 Differential effect of nicotine on D1 vs D2 antagonist-induced catalepsy. Emerich DF, Sanberg PR, Manderscheid PZ, McConville BJ, Rich JM, El-Etri MM, Shipley MT, Norman AB SOC NEUROSCI ABS VIEWER ITINERARY PLANNER (1990) 16 247 Abs 109.4
45. 09 Nicotine potentiation of haloperidol-induced catalepsy: Striatal mechanisms. Sanberg PR, Emerich DF, El-Etri MM, Shipley MT, Zanol MD, Cahill DW, Norman AB PHARMACOL BIOCHEM BEHAV (1993) 46 2 303-307
46. 47 Case study: Long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. Silver AA, Shytle RD, Philipp MK, Sanberg PR J AM ACAD CHILD ADOLESC PSYCHIATRY (1996) 35 12 1631-1636
47. 66 Neurobiology of attention deficit disorder with hyperactivity: Where have we come in 50 years? Zametkin AJ, Rapoport JL J AM ACAD CHILD ADOLESC PSYCHIATRY 1987 26 5 676-686
48. 86 Presynaptic modulation of transmitter release by nicotinic receptors. Wonnacott S, Irons J, Rapier C, Thome B, Lunt GG PROG BRAIN RES 1989 79 157-163
49. 3H]dopamine release from synaptosomes prepared from mouse striatum. Grady S, Marks MJ, Wonnacott S, Collins AC J NEUROCHEM 1992 59 3 848-856
50. 89 The effects of cholinergic and dopaminergic antagonists on nicotine-induced cerebral neurotransmitter changes. Rossi S, Singer S, Shearman E, Sershen H, Lajtha A NEUROCHEM RES 2005 30 4 4541-4558
51. 90 Dose-specific improvements in memory-related task performance by rats and aged monkeys administered the nicotinic-cholinergic antagonist mecamylamine. Terry AV Jr, Buccafusco JJ, Prendergast MA DRUG DEV RES 1999 47 3 127-136
52. 94 Titration of oral nicotine intake with smoking behaviour in monkeys. Glick SD, Zimmerberg B, Jarvik ME NATURE 1971 233 5316 207-208
53. 99 Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. Tennant FS Jr, Tarver AL, Rawson RA NIDA RES MONOGR 1984 49 239-246
54. 00 Withdrawal from nicotine dependence using mecamylamine: Comparison of three-week and six-week dosage schedules. Tennant FS Jr, Tarver AL NIDA RES MONOGR 1984 55 291-297
55. 01 Drug motivation and abuse: A neurobiological perspective. Di Chiara G, Acquas E, Carboni E ANN NY ACAD SCI 1992 654 207-219
56. 00 The neurobiology of drug addiction. Koob GF, Nestler EJ J NEUROPSYCHIATRY CLIN NEUROSCI 1997 9 3 482-497
57. 01 Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: Effects of acute and repeated injections. Vezina P, Blanc G, Glowinski J, Tassin JP J PHARMACOL EXP THER 1992 2612 484-490
58. 02 Nicotine and caffeine use in cocaine-dependent individuals. Budney AJ, Higgins ST, Hughes JR, Bickel WK J SUBST ABUSE 1993 5 2 117-130
59. 05 Mecamylamine decreases accumbal dopamine output in mice treated chronically with nicotine. Gaddnas H, Piepponen TP, Ahtee L NEUROSCI LETT 2002 330 3 219-222
60. 51 Is antagonism of α3β4 nicotinic receptors a strategy to reduce morphine dependence? Taraschenko OD, Panchal V, Maisonneuve IM, Glick SD EUR J PHARMACOL 2005 513 3 207-218
61. 58 Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Ericson M, Blomqvist O, Engel JA, Soderpalm B EUR J PHARMACOL 1998 358 3 189-196
62. 60 The nicotinic antagonist mecamylamine preferentially inhibits cocaine vs food self-administration in rats. Levin ED, Mead T, Rezvani AH, Rose JE, Gallivan C, Gross R PHYSIOL BEHAV 2000 71 5 565-570
63. 62 A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects. Reid MS, Mickalian JD, Delucchi KL, Berger SP NEUROPSYCHOPHARMACOLOGY 1999 20 3 297-307
64. 63 Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Blomqvist O, Hernandez-Avila CA, Van Kirk J, Rose JE, Kranzler HR ALCOHOL CLIN EXP RES 2002 26 3 326-331
65. 65 Mecamylamine and ethanol preference in healthy volunteers. Young EM, Mahler S, Chi H, de Wit H ALCOHOL CLIN EXP RES 2005 29 1 58-65
66. 71 Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. Fryer JD, Lukas RJ J NEUROCHEM 1999 72 3 1117-1124
67. 80 Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices. Hennings EC, Kiss JP, Vizi ES BRAIN RES 1997 759 2 292-294
68. 83 Nicotinic acetylcholine receptors as targets for antidepressants. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR MOL PSYCHIATRY 2002 7 6 525-535
69. 84 Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine). Shytle RD, Silver AA, Sanberg PR BIOL PSYCHIATRY 2000 48 10 1028-1031
70. 33 Influencing cigarette smoking with nicotine antagonists. Stolerman IP, Goldfarb T, Fink R, Jarvik ME PSYCHOPHARMACOLOGY 1973 28 3 247-259
71. 53 Nicotine-like behavioral effect after small dose of mecamylamine in Roman high-avoidance rats. Driscoll P PSYCHOPHARMACOLOGY 1976 46 1 119-121
72. 57 Anxiolytic effects of mecamylamine in two animal models of anxiety. Newman MB, Manresa JJ, Sanberg PR, Shytle RD EXP CLIN PSYCHOPHARMACOL 2002 10 1 18-25
73. 59 Pharmacological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine. Martin TJ, Suchocki J, May EL, Martin BR J PHARMACOL EXP THER 1990 254 1 45-51
74. 67 Drug Development Pipeline - Mecamylamine and TC-5214. Targacept Inc COMPANY WORLD WIDE WEB SITE 2006 January 26
75. 17 Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. Papke RL, Sandberg PR, Sytle RD J PHARMACOL EXP THER 2001 297 2 646-656
76. 40 Chemistry and structure-activity relationships of mecamylamine and derivatives. Stone CA, Torchiana ML, Sletzinger M, Stein GA, Ruyle WV, Reinhold DF, Gaines WA, Arnold H, Pfister III K J MED PHARM CHEM 1962 5 1 665-690
77. 77 Drug developemnt pipeline: TC-5231. Targacept Inc COMPANY COMMUNICATION 2006 January 19
78. 60 Agents acting at the neuromuscular junction and autonomic ganglia. Taylor P GOODMAN & GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS 11th Edition Eds: Brunton LL, Lazo JS, Parker KL McGraw-Hill Professional, Maidenhead, UK 2005 234
79. 71 Cognitive effects of acute nicotine and ultra low-dose mecamylamine in attention-deficit/hyperactivity disorder (ADHD). Potter A, Newhouse PA BIOL PSYCHIATRY 2005 57 69S